NCT03520712 - Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

August 7, 2024

Study Completion Date

August 7, 2024

Conditions

Hemophilia AGene TherapyClotting DisordersBlood Disorder

Interventions

BIOLOGICAL

Valoctocogene Roxaparvovec

Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Trial Locations (9)

Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center, Johannesburg

Kyung Hee University Hospital at Gangdong, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Tri-Service General Hospital, Taipei

Royal Free Hospital, London

University Hospital Southampton NHS Foundation Trust, Southampton